FDA gives Durham’s BioCryst green light to resume enrollment in multiple trials


A Durham drugmaker can resume enrolling patients in multiple clinical trials after getting the OK from regulators.

Previous Fire at Roseway Theater draws massive firefighting response
Next Berwyn estate with 'party barn' owned by the daughter of soap opera icon Agnes Nixon lists for $3.95M

No Comment

Leave a reply

Your email address will not be published.